Stem Cell Sciences Signs Service Agreement with Pfizer to Provide Access to Technologies and Methods

Stem Cell Sciences plc has signed a Master Service Agreement of up to five years with Pfizer Limited, the UK operating unit of the global research-based pharmaceutical company Pfizer, Inc. Under the terms of the agreement, SCS will provide research services, cell lines, media and reagents to support Pfizer's R&D efforts in this field.

Dr Alastair Riddell, CEO of SCS, said, "The opening of Pfizer's new regenerative medicine research facility in Cambridge, UK, last week is very important for stem cell research and reinforces the UK's position as an international centre of excellence. We are therefore very pleased to be able to support Pfizer's efforts to advance biomedical research under our new agreement."

The Pfizer regenerative medicine unit will be led by Chief Scientific Officer, Ruth McKernan, PhD, who said, "I'm very excited to lead this new research unit. While there is still a lot to understand about how stem cells can be used therapeutically, we believe it is one of the most promising areas of scientific research. Building successful partnerships with companies such as Stem Cell Sciences will be important for us."